



FOR IMMEDIATE RELEASE

October 2008

Ichor Medical Systems Leadership

Founded in 1994, Ichor has developed the only fully integrated push button electroporation device that allows effective, consistent and reproducible administration of DNA from patient to patient with minimal operator training or skill. The automated Ichor TriGrid™ Delivery System (TriGrid) enables total control of the site of injection, placement of electrodes, rate of agent administration, and timing of electroporation delivery. As a result, TriGrid makes the clinical application of electroporation easy, safe and effective, with DNA uptake enhanced by several orders of magnitude compared to conventional methods of delivery.

The development of the TriGrid and its rapidly expanding use in a wide range of pre-clinical and clinical studies around the world is being led by a management team with unequalled experience and expertise. The team includes:

Robert Bernard, President & CEO

Bob co-founded Ichor and led the team that invented the TriGrid platform technology and established its proof of concept. Throughout his business and professional career, he has developed an extensive background in the life sciences. He is a proven entrepreneur with experience managing and directing innovative technology-based companies. Prior to founding Ichor, he was president and founder of Bernard Foods, Inc., an innovative, technology-based food business that was acquired by Nestle in 1992. Bob served as Nestle vice president, new business development until founding Ichor. Bob received his degree in mechanical and electrical engineering from Louisiana State University.

Drew Hannaman, Vice President, Research and Development

Drew joined Ichor in 1995 after he earned his B.S. in Bioengineering/Cybernetics at the University of California, Los Angeles. He is a co-inventor of Ichor's TriGrid technology and designed and developed the company's experimental and clinical administration systems. He leads the multi-disciplinary team responsible for Ichor's DNA drug research, development, regulatory, and manufacturing activities and manages Ichor's collaborations and partnerships. Drew speaks at industry conferences on the future of electroporation for both prophylactic and therapeutic applications.

Claire Evans, Ph.D., Director, Therapeutic Programs

Claire joined Ichor as a Senior Research Scientist in 2003. Prior to this, she directed gene expression profiling programs at Digital Gene Technologies in the areas of multiple sclerosis, infectious diseases,



and mucosal vaccines. Formerly, she was an assistant professor at The Scripps Research Institute in the Department of Neuropharmacology where she ran research programs in central nervous system inflammation and demyelination, autoimmunity, and persistent viral infections. She has been a co-editor of the journal, *CNS & Neurological Disorders - Drug Targets* (formerly *Current Drug Targets - CNS and Neurological Disorders*), since 2002. Claire received her Ph.D. in Biological Chemistry at the University of Michigan, Ann Arbor. She is currently principal investigator on several Ichor projects.

Brian Livingston, Ph.D., Director, Vaccine Development: Biodefense & Emerging Infections

Brian came to Ichor in 2008 to lead several of Ichor's vaccine development programs. He has over 15 years of experience in research and development for infectious diseases. Prior to joining Ichor, Brian held director level positions in preclinical research at Dynavax Technologies and vaccine development at Epimmune, Inc. He received his Ph.D. in Biological Chemistry at the University of California, Los Angeles.

Karen E. Dolter, Ph.D., Senior Research Scientist

Karen joined Ichor in 2005 as a senior research scientist and currently designs, oversees, and interprets *in vitro* and *in vivo* experiments, including GLP preclinical safety studies, for developing and analyzing gene delivery and expression methods. She earned her Ph.D. in Microbiology/Immunology from the University of Michigan and her B.A. in Biochemistry-Molecular Biology at the University of California, Santa Barbara. Karen worked in postdoctoral positions at Wayne State University, La Jolla Cancer Research Foundation's Burnham Institute, and The Scripps Research Institute in the areas of molecular virology, tumor cell biology and gene regulation research. Prior to joining Ichor, Karen specialized in oncolytic recombinant herpesviruses as an assay development scientist at MediGene, Inc. and in RNA research as a staff scientist at Stratagene.

May de las Alas, Ph.D., Business Development

May first joined Ichor in 1999. In four years as research scientist, May was the project leader for the adaptation of Ichor's electroporation technology for delivery of plasmid DNA into muscle tissue. She earned her B.A. in Biology from Boston University and her Ph.D. in Biomedical Sciences from University of California, San Diego (UCSD). May then spent two years with Invitrogen Corp. as a senior technical support scientist, after which she returned to Ichor and now heads its business development efforts. Her responsibilities include developing contacts within major pharmaceutical and biotech companies, coordinating conference exhibitions, and arranging speaking engagements for Ichor senior management.

For additional inquiries, please contact:

Ichor Medical Systems – 858-550-2022

Dr. May de las Alas



mdelasalas@ichorms.com
Direct: 858-550-2022 x108